TriSalus Life Sciences Inc. announced the appointment of Liselotte Hyveled to its Board of Directors. Hyveled brings over twenty years of experience in stimulating scientific innovation and enabling pharmaceutical advancements through R&D excellence. She currently serves as Chief Patient Officer at Novo Nordisk and has led numerous socially responsible initiatives. TriSalus, under her guidance, aims to further commercialize their TriNav Infusion System and advance their innovative immunotherapy pipeline. The company focuses on delivering treatments for liver and pancreatic tumors employing its proprietary Pressure-Enabled Drug Delivery (PEDD) technology. The appointment aligns with TriSalus’ growth strategy as it seeks to enhance patient outcomes and scale operations.

Oncology, Medical Technology, Pharmaceutical Research & Development,United States, Denmark

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors